Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock Holdings Increased by Hood River Capital Management LLC

Hood River Capital Management LLC grew its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 4.1% in the second quarter, according to its most recent filing with the SEC. The firm owned 2,732,427 shares of the biotechnology company’s stock after acquiring an additional 108,189 shares during the quarter. Hood River Capital Management LLC’s holdings in Iovance Biotherapeutics were worth $21,914,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Victory Capital Management Inc. lifted its holdings in Iovance Biotherapeutics by 19.1% in the fourth quarter. Victory Capital Management Inc. now owns 26,921 shares of the biotechnology company’s stock worth $219,000 after purchasing an additional 4,323 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Iovance Biotherapeutics by 3.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,747,023 shares of the biotechnology company’s stock worth $14,203,000 after acquiring an additional 54,490 shares during the period. Vanguard Personalized Indexing Management LLC bought a new position in shares of Iovance Biotherapeutics in the fourth quarter valued at approximately $125,000. Quadrant Capital Group LLC increased its stake in shares of Iovance Biotherapeutics by 1,227.8% during the fourth quarter. Quadrant Capital Group LLC now owns 5,059 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 4,678 shares during the period. Finally, Norges Bank bought a new stake in Iovance Biotherapeutics during the fourth quarter worth approximately $9,109,000. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Stock Down 1.9 %

NASDAQ:IOVA opened at $10.15 on Monday. The stock has a fifty day simple moving average of $9.83 and a 200 day simple moving average of $10.65. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of -5.64 and a beta of 0.63. Iovance Biotherapeutics, Inc. has a 1-year low of $3.21 and a 1-year high of $18.33.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.01. Iovance Biotherapeutics had a negative net margin of 1,343.27% and a negative return on equity of 65.04%. The company had revenue of $31.11 million during the quarter, compared to analysts’ expectations of $24.59 million. During the same period last year, the company posted ($0.47) earnings per share. The business’s revenue for the quarter was up 12969.7% on a year-over-year basis. Equities analysts predict that Iovance Biotherapeutics, Inc. will post -1.26 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. JMP Securities decreased their price target on Iovance Biotherapeutics from $25.00 to $23.00 and set a “market outperform” rating for the company in a research note on Thursday, June 20th. Piper Sandler lowered Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $19.00 to $10.00 in a report on Monday, July 29th. HC Wainwright reiterated a “buy” rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a research report on Monday, August 12th. Finally, StockNews.com upgraded shares of Iovance Biotherapeutics to a “sell” rating in a research report on Monday, August 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.